It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What a ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a v ...

JHVEPhoto/iStock Editorial via Getty Images McKesson (NYSE:MCK) published their Q3 FY24 earnings on February 7th, reporting 15% topline growth and 12.2% adjusted EPS growth. I highlighted their growth opportunities in GLP-1 medications and their significant share buyback program in my introductory coverage. I maintain a 'Strong Buy' rating with a fair value of $660 per share. Strong GLP-1 Growth and Prior Authorization Network In Q3 FY24, McKesson delivered 15% revenue growth on a constant currency basi ...

McKesson Corporation (MCK) reported third-quarter fiscal 2024 adjusted earnings per share (EPS) of $7.74, which beat the Zacks Consensus Estimate of $7.05 by 9.8%. The bottom line also improved 12% on a year-over-year basis.GAAP EPS was $4.42, down 42% from the year-ago quarter’s level. The significant decline was due to the provision of bad debts worth $515 million for uncollected trade accounts receivable related to the bankruptcy of Rite Aid Corporation. Moreover, the company recorded a pre-tax benefit o ...

McKesson Corporation Third Quarter Fiscal 2024 Earnings Call Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,”“should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the ...

McKesson Corporation. (NYSE:MCK) Q3 2024 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Eric Percher - Nephron Research Lisa Gill - JPMorgan Allen Lutz - Bank of America Brian Tanquilut - Jefferies Kevin Caliendo - UBS Eric Coldwell - Baird Stephanie Davis - Barclays Erin Wright - Morgan Stanley Daniel Gros ...

McKesson (MCK) reported $80.9 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 14.8%. EPS of $7.74 for the same period compares to $6.90 a year ago.The reported revenue represents a surprise of +4.41% over the Zacks Consensus Estimate of $77.48 billion. With the consensus EPS estimate being $7.05, the EPS surprise was +9.79%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2024 third quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived o ...

Financial Performance - Revenues for the three months ended December 31, 2023, increased to $80,898 million, up from $70,490 million in the same period of 2022, representing a growth of 18.9%[8] - Gross profit for the nine months ended December 31, 2023, was $9,243 million, slightly down from $9,292 million in 2022, indicating a decrease of 0.5%[8] - Operating income for the three months ended December 31, 2023, was $642 million, compared to $1,241 million in the same period of 2022, reflecting a decline of 48.3%[8] - Net income attributable to McKesson Corporation for the three months ended December 31, 2023, was $589 million, down from $1,079 million in 2022, a decrease of 45.5%[9] - Net income for the nine months ended December 31, 2023, was $2,330 million, a decrease of 19.6% compared to $2,896 million in the same period of 2022[26] - The company reported an operating profit of $879 million for the three months ended December 31, 2023, compared to $1.4 billion in the same period of 2022[159] - Income from continuing operations attributable to McKesson Corporation was $589 million for the three months ended December 31, 2023, compared to $1,078 million in 2022[73] - Diluted earnings per share of $4.42 for the three months ended December 31, 2023, down from $7.66 in the same period of 2022[73] - Diluted earnings per common share from continuing operations decreased to $4.42 for the three months and $16.39 for the nine months ended December 31, 2023, down from $7.65 and $19.32, respectively, in the prior year[178] Cash Flow and Liquidity - Cash and cash equivalents decreased to $1,982 million as of December 31, 2023, from $4,678 million as of March 31, 2023, a decline of 57.7%[13] - Cash provided by operating activities significantly decreased to $167 million from $1,834 million year-over-year[26] - Total cash, cash equivalents, and restricted cash at the end of the period was $1,982 million, down from $2,774 million a year earlier[26] - The company reported a net cash used in financing activities of $2,374 million, compared to $3,178 million in the previous year[26] - The company recognized a total gain of $9 million on debt extinguishments for the nine months ended December 31, 2023[89] Debt and Financing - Long-term debt rose to $5,625 million as of December 31, 2023, from $4,626 million as of March 31, 2023, an increase of 21.6%[13] - The company’s long-term debt issuances increased to $991 million from $499 million year-over-year[26] - The company completed a public offering of 4.90% Notes due July 15, 2028, for $400 million and 5.10% Notes due July 15, 2033, for $600 million[85] - The company repurchased $271 million principal amount of its 2024 Notes for $268 million in a Concurrent Tender Offer[87] - The company has a $4.0 billion senior unsecured credit facility, with the maturity date extended to November 2028[91] - As of December 31, 2023, the company had $218 million in commercial paper notes outstanding at a weighted average interest rate of 5.53%[92] Shareholder Returns - Cash dividends declared were $0.62 per common share for the three months ended December 31, 2023, compared to $0.54 per common share in the same period of 2022, an increase of 14.8%[10] - The company returned $2.6 billion to shareholders during the nine months ended December 31, 2023, through $2.3 billion in stock repurchases and $232 million in dividend payments[179] - During the three months ended December 31, 2023, the Company repurchased 1.9 million shares of common stock for $868 million at an average price of $457.16 per share[139] - The Company repurchased a total of 3.1 million shares under the ASR program at an average price of $321.05, totaling $1.0 billion[141] - An additional ASR program was initiated for $1.5 billion, resulting in the repurchase of 5.1 million shares at an average price of $295.16[144] - As of December 31, 2023, the total remaining authorization for stock repurchases was $7.3 billion[144] Acquisitions and Investments - The company completed the acquisition of Rx Savings Solutions, LLC for a total consideration of $692 million, including $600 million in cash and $92 million in contingent consideration[40][41] - McKesson formed SCRI Oncology, LLC with HCA Healthcare, acquiring a 51% controlling interest and paying $166 million in cash[45][46] - The company recognized fair value adjustment gains of $78 million on contingent consideration related to Rx Savings Solutions during the nine months ended December 31, 2023[41] - The carrying value of investments in equity securities of U.S. growth stage companies was $213 million at December 31, 2023[111] Legal and Regulatory Matters - The Company has paid approximately $1.5 billion to settling governmental entities as part of a settlement agreement, with an additional commitment of up to $6.3 billion through 2038[125] - The Company has made payments totaling $529 million associated with opioid-related settlements during the nine months ended December 31, 2023[128] - The Company has paid approximately $84 million to federally recognized Native American tribes as part of opioid-related claims, with an additional commitment of approximately $112 million through 2027[127] - The Company is involved in approximately 400 opioid-related cases brought by private plaintiffs, which are not included in the settlement agreements[129] - The Company has accrued liabilities for opioid-related claims, reflecting ongoing legal uncertainties and potential future losses[121] - The Company intends to vigorously defend itself against all opioid-related claims, asserting valid legal defenses[132] Operational Metrics - The U.S. Pharmaceutical segment generated revenues of $73.0 billion for the three months ended December 31, 2023, compared to $61.9 billion in 2022, reflecting a growth of approximately 18%[162] - The Prescription Technology Solutions segment reported revenues of $1.2 billion for the three months ended December 31, 2023, up from $1.1 billion in 2022[162] - The Medical-Surgical Solutions segment achieved revenues of $3.0 billion for the three months ended December 31, 2023, slightly increasing from $3.0 billion in 2022[162] - The International segment's revenues decreased to $3.6 billion for the three months ended December 31, 2023, down from $4.4 billion in 2022[162] - The provision for bad debts related to the bankruptcy of Rite Aid Corporation amounted to $515 million for the three months and $725 million for the nine months ended December 31, 2023[178] Tax Matters - The Company recognized a net discrete tax benefit of $141 million during the three months ended December 31, 2023, primarily due to the release of a valuation allowance[67] - As of December 31, 2023, the Company had $1.4 billion of unrecognized tax benefits, with $1.3 billion potentially reducing income tax expense if recognized[68] - A discrete tax benefit of $154 million was recognized for the three months ended December 31, 2023, related to the release of a valuation allowance on deferred tax assets[179] Restructuring and Impairment - The company incurred restructuring, impairment, and related charges of $4 million for the three months ended December 31, 2023, compared to $31 million in the same period of 2022, indicating a significant reduction in such charges[8] - Total restructuring charges anticipated across segments are approximately $125 million, with $101 million recorded through December 31, 2023[59] - Corporate restructuring charges amounted to $50 million for the nine months ended December 31, 2023, compared to $38 million in the prior year[178]

Shares of McKesson (MCK) have been strong performers lately, with the stock up 5.5% over the past month. The stock hit a new 52-week high of $508.09 in the previous session. McKesson has gained 9% since the start of the year compared to the 3.6% move for the Zacks Medical sector and the 1.8% return for the Zacks Medical - Dental Supplies industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the l ...